Drugs & Targets FDA grants marketing authorization to Parsortix System for liquid biopsy in MBC May 27, 2022Vol.48 No.21
Drugs & Targets FDA approves Tibsovo + Vidaza in IDH1-mutant newly diagnosed AML May 27, 2022Vol.48 No.21
Drugs & Targets Friends study: drugs that earn Breakthrough Therapy Designation at FDA provide maximum benefit in lung cancer May 27, 2022Vol.48 No.21
Drugs & Targets EMA adopts positive opinion for Keytruda in melanoma following complete resection May 27, 2022Vol.48 No.21
Drugs & Targets Case Western, Picture Health partner to develop AI tools for lung cancer May 27, 2022Vol.48 No.21
Drugs & Targets AmerisourceBergen establishes Clinical Trial Navigator tool to increase access to research opportunities May 27, 2022Vol.48 No.21
Conversation with The Cancer Letter Jon Chernoff pledges to revive his institution’s “Fox Chaseness” after years of setbacks May 20, 2022Vol.48 No.20By Paul Goldberg
In Brief UICC forms global coalition to increase access to cancer care in LLMICs May 20, 2022Vol.48 No.20
In Brief ARPA-H, diversity in clinical trials bills advance through committee May 20, 2022Vol.48 No.20
